A substantial jump of 29.26% was observed in the stock valuation of Altamira Therapeutics Ltd. (NASDAQ: CYTO) during the previous trading session, which was capped by a $2.43 closing price. Despite the absence of significant pertinent news, this remarkable upturn prompted a closer examination of the stock’s performance, directing attention towards recent developments.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Altamira Therapeutics (CYTO) recently disclosed the publication of a meticulously scrutinized article in the Journal of Integrative Medicine titled, “Enhancement of Recombinant Adeno-Associated Virus Transduction Efficiency through Melittin Analog p5RHH”.
This scholarly work delves into the exploration of various peptides aimed at bolstering adeno-associated virus (AAV) cell transduction and was conducted by an autonomous research consortium. Nucleic acids are frequently introduced into cells using AAV recombinant vectors for gene therapy applications, and a number of FDA-approved drugs derived from AAV vectors are currently on the market.
In this work, the endosomal release of AAV-based therapies was improved by the application of melittin, a bee venom component recognized for its capacity to cross biological membranes. The research collective scrutinized 76 melittin derivatives, encompassing p5RHH, the foundational peptide underlying Altamira’s OligoPhore/SemaPhore nanoparticle platform for RNA delivery.
The researchers ascertained that the incorporation of p5RHH into the AAV vector (p5RHH-rAAV) not only amplified cell transduction but also demonstrated efficacy in transducing cell lines traditionally deemed resistant to AAVs.
Furthermore, an in vivo examination in mice demonstrated that the adjunct of p5RHH to the AAV capsid of various AAV serotypes substantially enhanced liver transduction compared to unmodified AAV vectors, as evidenced up to the final time point, four weeks post systemic administration.
These findings once again underscore the robust capacity of CYTO’s technology in facilitating the liberation of nucleic acids from the endosome into the cytoplasm, a longstanding pivotal limitation for both non-viral vectors and viral-derived delivery platforms like AAVs.
Enhanced transduction efficiency implies the potential for administering lower doses of AAVs, thereby mitigating the risk of adverse immune responses and heightening the safety profile of AAV-based vectors.
Additionally, the integration of the p5RHH peptide into diverse serotypes of AAV vectors may herald novel prospects in AAV-based gene therapy for cells and tissues traditionally impervious to AAV transduction.
